Literature DB >> 28895630

[Changes in OCT Angiography of Type 2 CNV in Neovascular AMD during Anti-VEGF Treatment].

Henrik Faatz1, Kai Rothaus1, Frederic Gunnemann1, Matthias Gutfleisch1, Britta Heimes-Bussmann1, Albrecht Lommatzsch1,2, Daniel Pauleikhoff1,2, Marie-Louise Farecki1.   

Abstract

Purpose OCT-A is a new method to visualise the 2D and 3D structures of neovascular complexes in exudative AMD. The aim of the present study was to characterise type 2 CNV in different 2D segmentations and in 3D imaging and to investigate changes during anti-VEGF treatment. Methods 12 patients with type 2 CNV in FA and SD-OCT were selected. OCT-A (Avanti, Optovue) was obtained initially and after the first three injections and thereafter, if "new activity" (increase in sub- or intraretinal fluid) occurred. The characteristics of the type 2 CNV were classified initially and during follow-up in different segmentations (outer retina, RPE, CC, choroidea), in respect to the size of the CNV, the flow area within the CNV and flow index (% of flow area within the total lesion). Results Comparison of the vessel characteristics before and after anti-VEGF treatment showed a significant reduction in the size of CNV at every level (p < 0.05). This was most significant at the RPE level (p < 0.005). After new activity, a significant increase in size was only recognised at the CC level (p < 0.05). Similarly, the most significant changes in the flow area were measured at the RPE level before and after treatment (p < 0.01) and at the CC level after new activity (p < 0.05). Demarcation from type 2 CNV of the bordering tissue was much better when activity occurred. Conclusions OCT-A provides a new opportunity for the assessment of vascular characteristics of type 2 CNV, and quantifies CNV size and vascularisation under anti-VEGF therapy. This may be used in further studies in combination with SD-OCT scans to describe characteristics of this type of CNV under treatment. OCT-A is an additional medical imaging procedure to SD-OCT and FA, but more experience is needed in distinguishing CNV in the active and non-active stages. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28895630     DOI: 10.1055/s-0043-118346

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  4 in total

1.  Optical coherence tomography angiography of types 1 and 2 choroidal neovascularization in age-related macular degeneration during anti-VEGF therapy: evaluation of a new quantitative method.

Authors:  Henrik Faatz; Marie-Louise Farecki; Kai Rothaus; Frederic Gunnemann; Matthias Gutfleisch; Albrecht Lommatzsch; Daniel Pauleikhoff
Journal:  Eye (Lond)       Date:  2019-04-10       Impact factor: 3.775

Review 2.  Imaging endpoints for clinical trials in MacTel type 2.

Authors:  Daniel Pauleikhoff; Laurenz Pauleikhoff; Emily Y Chew
Journal:  Eye (Lond)       Date:  2021-08-13       Impact factor: 3.775

Review 3.  Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms.

Authors:  Shreya Somasundaran; Ian J Constable; Carla B Mellough; Livia S Carvalho
Journal:  Clin Exp Ophthalmol       Date:  2020-08-17       Impact factor: 4.207

4.  Axial Stretching of Vessels in the Retinal Vascular Plexus With 3D OCT-Angiography.

Authors:  Julian Johannes Kuhlmann; Kai Rothaus; Xiaoyi Jiang; Britta Heimes-Bussmann; Henrik Faatz; Marius Book; Daniel Pauleikhoff
Journal:  Transl Vis Sci Technol       Date:  2022-02-01       Impact factor: 3.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.